Development of VIP agonists and antagonists with tissue and receptor specificity: effects on behavioral maturation, sexual function, and the biologic clock.
Gozes
I
I
Department of Clinical Biochemistry, Sackler School of Medicine, Tel Aviv University, Israel. igozes@post.tau.ac.il
Lilling
G
G
Davidson
A
A
Bardea
A
A
Reshef
A
A
Glazer
R
R
Zamostiano
R
R
Ashur-Fabian
O
O
Ticher
A
A
Ashkenazi
I E
IE
Moody
T W
TW
Rubinraut
S
S
Fridkin
M
M
Brenneman
D E
DE
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects*; D002490:Central Nervous System / Q000187:drug effects / Q000502:physiology; D015195:Drug Design; D007172:Erectile Dysfunction / Q000188:drug therapy; D006801:Humans; D008297:Male; D008322:Mammals; D009043:Motor Activity / Q000187:drug effects; D010507:Periodicity; D051236:Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide; D011979:Receptors, Pituitary Hormone / Q000187:drug effects / Q000502:physiology; D018005:Receptors, Vasoactive Intestinal Peptide / Q000187:drug effects / Q000378:metabolism / Q000502:physiology*; D012726:Sexual Behavior, Animal / Q000187:drug effects*; D013379:Substrate Specificity; D014660:Vasoactive Intestinal Peptide / Q000819:agonists* / Q000037:antagonists & inhibitors* / Q000138:chemical synthesis
D051236:Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide; D011979:Receptors, Pituitary Hormone; D018005:Receptors, Vasoactive Intestinal Peptide; D014660:Vasoactive Intestinal Peptide